Dosimetry and thyroid cancer: the individual dosage of radioiodine.

Adjuvant therapy of differentiated thyroid cancer with radioactive iodine ((131)I) is a standard procedure for the ablation of remnant thyroid tissue following surgery and for the treatment of iodine-avid metastases. Presently, there are two dosimetric concepts for the treatment of thyroid cancer using radioiodine: a) the bone marrow dose limited approach and b) lesion-based dosimetry. Both concepts and their clinical applications are described. In addition, the use of (124)I as a diagnostic and dosimetric agent is discussed. Treatment of children and adolescents with radioiodine requires special precautions; individualized approaches in this setting are reviewed. The limitations of treatments aiming at high absorbed doses are addressed as well as the doses to normal organs. Finally, new concepts for further elaborating the potential of thyroid cancer treatment using (131)I are introduced.

[1]  C. Manni,et al.  The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[2]  C. Harmer,et al.  Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy , 2004, Nuclear medicine communications.

[3]  S. Gulec,et al.  Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  R G Dale,et al.  Dose-rate effects in targeted radiotherapy. , 1996, Physics in medicine and biology.

[5]  M. Medvedec.  Thyroid stunning in vivo and in vitro , 2005, Nuclear medicine communications.

[6]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[7]  A. Samuel,et al.  Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  A. Bockisch,et al.  Optimized 124 I PET Dosimetry Protocol for Radioiodine Therapy of Differentiated Thyroid Cancer , 2008 .

[9]  R. Wahl,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. , 2006, The Journal of clinical endocrinology and metabolism.

[10]  M. Luster,et al.  Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  R. Wahl,et al.  Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  D. van Nostrand,et al.  The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[13]  Wesley E. Bolch,et al.  MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature , 2009, Journal of Nuclear Medicine.

[14]  M R Castellani,et al.  Individualized dosimetry in the management of metastatic differentiated thyroid cancer. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[15]  M. Schlumberger,et al.  131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients , 2008, Journal of Nuclear Medicine.

[16]  A. Bockisch,et al.  Thyroid Remnant Dose: 124I-PET/CT Dosimetric Comparison of rhTSH versus Thyroid Hormone Withholding Before Radioiodine Remnant Ablation in Differentiated Thyroid Cancer , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[17]  Jamal Zweit,et al.  Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography , 1997, European Journal of Nuclear Medicine.

[18]  R. Wahl,et al.  Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging–Based Internal Dosimetry , 2007, Journal of Nuclear Medicine.

[19]  S. Larson,et al.  Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  George Sgouros,et al.  Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  Glenn D. Flux,et al.  A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  A. Bockisch,et al.  Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  Markus Luster,et al.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  M. Sperling,et al.  Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. , 1993, Nuclear medicine and biology.

[25]  M. Kreissl,et al.  Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  G. Barendsen,et al.  Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. , 1982, International journal of radiation oncology, biology, physics.

[27]  T. Fahey.  Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study , 2007 .

[28]  W. Oyen,et al.  Guidelines for radioiodine therapy of differentiated thyroid cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  M. Luster,et al.  Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  A. Bockisch,et al.  Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer , 2006, Nuclear medicine communications.

[31]  Z. Hall.  Cancer , 1906, The Hospital.

[32]  M. Luster,et al.  EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  M. Luster,et al.  Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  H. Scherthan,et al.  In Vivo Formation of γ-H2AX and 53BP1 DNA Repair Foci in Blood Cells After Radioiodine Therapy of Differentiated Thyroid Cancer , 2010, The Journal of Nuclear Medicine.

[35]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  J. Humm,et al.  Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  M. Sonenberg,et al.  The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.

[38]  J. O’Donoghue,et al.  Implications of nonuniform tumor doses for radioimmunotherapy. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  D. van Nostrand,et al.  Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. , 2002, Thyroid : official journal of the American Thyroid Association.

[40]  S. Larson,et al.  Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  R. Kloos,et al.  Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. , 2009, Endocrine-related cancer.

[42]  Howard S. Smith,et al.  Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. , 1990, Endocrinology and metabolism clinics of North America.

[43]  L. Freudenberg,et al.  Thyroid cancer in childhood: management strategy, including dosimetry and long-term results. , 2007, Hormones.

[44]  G. Reischl,et al.  Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  Martin A. Lodge,et al.  124I PET-Based 3D-RD Dosimetry for a Pediatric Thyroid Cancer Patient: Real-Time Treatment Planning and Methodologic Comparison , 2009, Journal of Nuclear Medicine.

[46]  B. Wessels,et al.  MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  P DESAIVE,et al.  [Thyroid cancer]. , 1951, Revue medicale de Liege.

[48]  A. Bockisch,et al.  124I-PET dosimetry in advanced differentiated thyroid cancer: Therapeutic impact , 2007, Nuklearmedizin.

[49]  R. Dierckx,et al.  Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[50]  E. Silberstein,et al.  Procedure guideline for therapy of thyroid disease with (131)iodine. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  Sungeun Kim,et al.  Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma , 2008, Annals of nuclear medicine.

[52]  K S Pentlow,et al.  Quantitative imaging of iodine-124 with PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[53]  V S Hertzberg,et al.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. , 1983, The New England journal of medicine.

[54]  Wei Bo Li,et al.  Track Structures and Dose Distributions from Decays of 131I and 125I in and around Water Spheres Simulating Micrometastases of Differentiated Thyroid Cancer , 2001, Radiation research.

[55]  H. Biersack,et al.  "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.